We welcome you to GTC's 3rd Pharmacokinetics & Pharmacodynamics Conference, taking place on October 24-26, 2012 in Philadelphia, PA. This year the conference is exclusively designed to showcase the state-of-the-art methodologies in the field of PK/PD, which would define the future of the field, and maximize the probability of achieving clinical success for drug companies. Cutting edge examples about the application of PK/PD analysis and modeling will be presented, that can help a drug company choose appropriate drug candidate, minimize clinical attrition, improve preclinical-to-clinical translation, and predict clinical outcome.
Key challenges faced by a PK/PD scientist will be addressed and approaches to overcome the challenges will be demonstrated. One would also learn about: (a) the use of PK/PD principles to overcome biological barriers e.g. BBB (b) effective translation of preclinical data into the clinic (c) utilization of PK/PD analysis and modeling to identify and validate appropriate biomarkers (d) perspective of the regulatory authorities regarding the use of PK/PD in streamlining the drug development (e) FIH dose prediction to achieve maximum efficacy and reduce the toxicity (f) development and utilization of systems pharmacology model to integrate known molecular pathways to validate drug targets.
The conference will be a very valuable tool for preclinical or clinical scientists and managers, working in the field of PK/PD, who are striving to use the PK/PD principles to minimize drug development risk and maximize clinical success. The sessions for our 2012 agenda are shown below.
More about the Event
Key challenges faced by a PK/PD scientist will be addressed and approaches to overcome the challenges will be demonstrated. One would also learn about: (a) the use of PK/PD principles to overcome biological barriers e.g. BBB (b) effective translation of preclinical data into the clinic (c) utilization of PK/PD analysis and modeling to identify and validate appropriate biomarkers (d) perspective of the regulatory authorities regarding the use of PK/PD in streamlining the drug development (e) FIH dose prediction to achieve maximum efficacy and reduce the toxicity (f) development and utilization of systems pharmacology model to integrate known molecular pathways to validate drug targets.
The conference will be a very valuable tool for preclinical or clinical scientists and managers, working in the field of PK/PD, who are striving to use the PK/PD principles to minimize drug development risk and maximize clinical success. The sessions for our 2012 agenda are shown below.
More about the Event
